NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Wednesday that its first quarter earnings rose 21 percent year over year.

For the three months ended March 31, the company reported revenues of $16.4 million, up from $13.6 million a year earlier, but missing the average analyst estimate for revenues of $17.7 million.

Veracyte said volume of its Afirma Gene Expression Classifier test rose 9 percent during Q1 to 5,834 tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.